Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the recombinant non-immunogenic staphylokinase in patients who have suffered an acute ischemic stroke within 4.5 to 24 hours after symptom onset. This phase III, multicenter, double-blind, randomized, placebo-controlled trial focuses on patients with large vessel occlusion in the anterior circulation and salvageable brain tissue. The study aims to determine if this treatment is effective and safe when given beyond the currently recommended 4.5-hour window for intravenous thrombolysis. Participants will be randomly assigned to receive either a single intravenous bolus of 10 mg non-immunogenic staphylokinase or a placebo injection immediately after randomization. The bolus is administered rapidly within 5 to 10 seconds and is not adjusted by body weight. Patients intended for direct thrombectomy are excluded. The study includes a follow-up period of 90 days to assess outcomes. During the trial, participants will undergo neuroimaging assessments such as CT or MRI to confirm eligibility and monitor brain perfusion. Researchers will measure functional outcomes using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days. They will also monitor reperfusion rates, mortality, and any adverse events. This comprehensive evaluation will help assess the treatments impact on restoring blood flow and improving recovery after stroke.